<- Go Home

SOPHiA GENETICS SA

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Market Cap

$669.1M

Volume

132.6K

Cash and Equivalents

$107.7M

EBITDA

-$71.7M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$57.4M

Profit Margin

66.63%

52 Week High

$8.98

52 Week Low

$3.12

Dividend

N/A

Price / Book Value

8.05

Price / Earnings

-6.78

Price / Tangible Book Value

14.25

Enterprise Value

$623.3M

Enterprise Value / EBITDA

-8.96

Operating Income

-$73.7M

Return on Equity

101.22%

Return on Assets

-24.52

Cash and Short Term Investments

$107.7M

Debt

$61.8M

Equity

$83.1M

Revenue

$86.2M

Unlevered FCF

-$21.5M

Sector

Health Care Technology

Category

N/A

Company Stock Pitches